文献速递自身免疫性与大疱性皮肤病药疹与重症皮肤不良反应

与抗程序性细胞死亡1治疗相关的亚急性皮肤红斑狼疮和皮肌炎

Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy.
PubMed 文献 · Br J Dermatol · 2018-12-10

本文报告两例转移性肺癌患者在接受PD-1抑制剂治疗后出现符合亚急性皮肤红斑狼疮(SCLE)的临床和组织学表现。第一例经全身和局部激素、光防护及羟氯喹治疗后好转,但继续PD-1抑制剂治疗后发生皮肌炎;第二例停用抗PD-1治疗并予全身激素和英夫利西单抗后皮疹仍迁延,加用局部激素和光防护并停用抗肿瘤坏死因子治疗后SCLE消退。作者将SCLE和皮肌炎列入PD-1阻断的自身免疫并发症清单。

要点

  • PD-1抑制剂相关SCLE经全身和局部激素、光防护及羟氯喹治疗可好转。
  • 继续PD-1抑制剂治疗可在SCLE后发生皮肌炎。
  • 停用抗PD-1及抗TNF治疗后加用局部激素和光防护可使SCLE消退。

核心结论

  • 作者将SCLE和皮肌炎加入PD-1阻断不断增多的自身免疫并发症清单。
  • 本文病例提出继续抗PD-1治疗及免疫抑制治疗在PD-1抑制剂相关结缔组织病中作用的问题。

研究设计与样本

  • 本文描述两例接受PD-1抑制剂治疗转移性肺癌后出现SCLE的患者。

主要发现

  • 第一例经全身和局部激素、光防护及羟氯喹治疗成功,但继续PD-1抑制剂治疗后发生皮肌炎。
  • 第二例停用抗PD-1治疗并予全身激素和英夫利西单抗后皮疹仍迁延,加用局部激素和光防护并停用抗TNF治疗后SCLE消退。
  • 第二例因肿瘤无反应,与肿瘤团队决定采用非PD-1抑制剂治疗肺癌。

临床怎么用

  • 作者报告第一例SCLE经全身和局部激素、光防护及羟氯喹治疗成功。
  • 第二例在加用局部激素和光防护并停用抗TNF治疗后SCLE消退。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Programmed cell death 1 (PD-1) blockade has rapidly emerged as an effective therapy for a wide variety of metastatic malignancies. It has been associated with multiple immune-related adverse effects, including cutaneous eruptions. We describe two patients with clinical and histological findings that were consistent with subacute cutaneous lupus erythematosus (SCLE) after receiving PD-1 inhibitor therapy for metastatic lung cancer. We successfully treated our first patient with systemic and topical steroids, photoprotection and hydroxychloroquine. However, he subsequently developed dermatomyositis after continuing PD-1 inhibitor therapy. Our second patient presented with a protracted course of a cutaneous eruption in spite of discontinuation of anti-PD-1 therapy and treatment with systemic corticosteroids and infliximab. This patient's SCLE resolved after the addition of topical steroids and photoprotection and discontinuation of anti-tumour necrosis factor therapy. She and her oncology team decided to pursue non-PD-1 inhibitor treatment for lung cancer owing to a lack of tumour response. We add SCLE and dermatomyositis to the growing list of autoimmune complications of PD-1 blockade. Our cases raise a number of questions, particularly in relation to the viability of continuing anti-PD-1 therapy after developing SCLE and the role of immunosuppressive therapy in patients with PD-1 inhibitor-associated connective tissue disease. What's already known about this topic? Programmed cell death 1 (PD-1) blockade, which is rapidly emerging as a therapy for a wide variety of metastatic malignancies, has been associated with multiple immune-related adverse effects. These include systemic autoimmune diseases such as colitis and thyroiditis in addition to numerous cutaneous adverse events. Cutaneous side-effects of PD-1 inhibitors most commonly reported in clinical trials include lichenoid reactions, eczematous dermatitis and vitiligo. What does this study add? We report two cases of PD-1 inhibitor-associated subacute cutaneous lupus erythematosus (SCLE), with one patient progressing to dermatomyositis with continued PD-1 inhibitor treatment. In addition to being a novel cutaneous adverse event, we also demonstrate the possibility of development of multiple autoimmune diseases in one patient, which is different from classic drug-related SCLE. We discuss the treatment challenges for patients with autoimmune skin disease receiving PD-1 inhibitor therapy.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Marano AL, Clarke JM, Morse MA, et al. Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. Br J Dermatol. 2018. PMID: 30244487. doi:10.1111/bjd.17245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。